STOCK TITAN

TREACE SHAREHOLDER ACTION REMINDER

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Negative)
Tags

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Treace To Contact Him Directly To Discuss Their Options

NEW YORK, Nov. 30, 2022 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Treace Medical Concepts, Inc. ("Treace" or the "Company") (NASDAQ: TMCI).

If you suffered losses exceeding $50,000 investing in Treace stock or options and would like to discuss your legal rights, call Faruqi & Faruqi partner Josh Wilson directly at 877-247-4292 or 212-983-9330 (Ext. 1310). You may also click here for additional information: www.faruqilaw.com/TMCI.

There is no cost or obligation to you.

Faruqi & Faruqi is a leading minority and Woman-owned national securities law firm with offices in New York, Pennsylvania, California and Georgia.

On November 15, 2022, Culper Research published a short report on Treace (the "Culper Report"). The Culper Report expressed the "view that Treace's primary innovation has not been in any sort of medical advancements, but in aggressive reimbursement practices and deceptive DTC marketing," which the Culper Report described "as problematic and self-defeating, as insurers appear to have begun placing Lapiplasty procedure reimbursements under scrutiny while customer complaints about misleading claims from Treace are mounting."

On this news, Treace's stock price fell $3.57 per share, or 14.81%, to close at $20.54 per share on November 15, 2022.

Attorney Advertising.  The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com).  Prior results do not guarantee or predict a similar outcome with respect to any future matter.  We welcome the opportunity to discuss your particular case.  All communications will be treated in a confidential manner.

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/treace-shareholder-action-reminder-301690883.html

SOURCE Faruqi & Faruqi, LLP

Treace Medical Concepts, Inc.

NASDAQ:TMCI

TMCI Rankings

TMCI Latest News

TMCI Stock Data

319.96M
44.28M
25.91%
67.56%
4.27%
Surgical and Medical Instrument Manufacturing
Manufacturing
Link
United States of America
PONTE VEDRA

About TMCI

treace medical concepts, inc. is a privately-funded, commercial stage company focused on bringing breakthrough technologies to the high-growth $1.1 billion us market for foot and ankle surgical products. we are committed to operating our business with the highest standards of ethical conduct. we will exceed our customers’ expectations through an innovation-driven, high-velocity approach to solving treatment and surgical problems. with our products and services, our mission is to assist foot and ankle physicians in improving patient outcomes and reducing healthcare costs, while providing a rewarding experience for our employees and an exceptional return for our shareholders.